Details

Details

Title Ohio Brain Tumor Study (OBTS)

IRB CASE1307

CC 296

Hospital Main Campus

Disease Brain

Description

Description

Primary Objective

To objectively characterize subtypes of primary benign and malignant brain tumors using genetic and environmental exposure information and associate these with clinical outcome.

Inclusion Criteria

Inclusion Criteria

  1. Subjects are newly diagnosed (i.e. within one month of histopathological and/or radiological diagnosis) primary benign and malignant brain tumor patients. All individuals are 18 years or older (i.e. adults only). All subjects are required to have radiological and/or histopathological confirmation of their brain tumor diagnosis. Radiological confirmation of brain tumor diagnosis will be obtained from radiology records from University Hospitals Case Medical Center (UHCMC), Cleveland Clinic Foundation (CCF), the Ohio State University Medical Center (OSU) or University of Cincinnati (UC). Histopathological confirmation of brain tumor diagnosis will be obtained via confirmation from UHCMC, CCF, OSU or U C pathology departments at from either a biopsy or a surgical specimen.
  2. Subjects are newly diagnosed and treated at UHCMC, CCF, OSU or UC. All subjects must be able to understand and sign the informed consent to be eligible.
  3. If the subject is impaired as a result of their brain tumor and they have a legal representative, the legal representative can consent for study on the patient�s behalf (proxy consent) and a proxy interview will be obtained.
  4. Subjects who are having a second surgery on their original tumor (i.e. the first surgery was a subtotal resection only), with no other treatments, are eligible.
Exclusion Criteria

Exclusion Criteria

  1. Subjects with a recurrent brain tumor are not eligible for this study.
  2. Subjects who are not willing or able to sign the consent or do not have a legal representative are not eligible for this study.
  3. Subjects who are pregnant are not eligible for this study.
  4. If a subject is deemed ineligible after consenting for this study (i.e. metastatic disease or recurrence), their data will be removed from study databases and biological specimens destroyed.
    • 1.Subjects may choose to discontinue their participation in the study at any time by notifying the PI.
    • To disenroll from the study individuals are asked to send a written letter to the PI listed on the informed consent.
    • Their data is then excluded from all future IRB-approved research studies effective immediately upon receipt of the request.